Abstract
Oxidant stress [ OS ] is a condition in which cells are exposed to excessive levels of either molecular oxygen or chemical derivatives of oxygen called reactive oxygen species [ROS], principal amongst which is superoxide [O2 -]. It is becoming increasingly apparent that O2 - is a key risk factor for cardiovascular disease [CVD], including atherogenesis, reperfusion injury, angina, restenosis following balloon angioplasty and vein graft failure. When one considers the multiplicity of effects of O2 -, this is perhaps not surprising, as it promotes vascular smooth muscle cell proliferation, damages the endothelium, promotes lipid oxidation and activates blood cells. However, perhaps the key reaction of O2 - is that with nitric oxide [NO] to form peroxynitrite [ONOO] resulting in a depletion of endogenous vascular NO. Reduced NO formation is also now firmly associated with the aetiology of CVD and as such NO donors may become a major class of drugs. Furthermore, risk factors for CVD, in particular diabetes mellitus [DM], dyslipidaemia, and hyperhomocysteinaemia are all associated with OS. As such, it is becoming increasingly apparent that novel antioxidant therapies, including the gene transfer of antioxidant enzymes, are potentially valuable in the treatment of CVD. In this review, the aetiology of OS and CVD is discussed with particular emphasis on NO. The interactions of risk factors and how this pathophysiology relates to the design of effective novel strategies to treat CVD is also considered. Particular emphasis is also placed on OS and cardiovascular surgery.
Keywords: oxidative stress, nitric oxide, vascular disease, cardiovascular surgery
Current Vascular Pharmacology
Title: Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Volume: 2 Issue: 3
Author(s): Jamie Y. Jeremy, Nilima Shukla, Saima Muzaffar, Alexandra Handley and Gianni D. Angelini
Affiliation:
Keywords: oxidative stress, nitric oxide, vascular disease, cardiovascular surgery
Abstract: Oxidant stress [ OS ] is a condition in which cells are exposed to excessive levels of either molecular oxygen or chemical derivatives of oxygen called reactive oxygen species [ROS], principal amongst which is superoxide [O2 -]. It is becoming increasingly apparent that O2 - is a key risk factor for cardiovascular disease [CVD], including atherogenesis, reperfusion injury, angina, restenosis following balloon angioplasty and vein graft failure. When one considers the multiplicity of effects of O2 -, this is perhaps not surprising, as it promotes vascular smooth muscle cell proliferation, damages the endothelium, promotes lipid oxidation and activates blood cells. However, perhaps the key reaction of O2 - is that with nitric oxide [NO] to form peroxynitrite [ONOO] resulting in a depletion of endogenous vascular NO. Reduced NO formation is also now firmly associated with the aetiology of CVD and as such NO donors may become a major class of drugs. Furthermore, risk factors for CVD, in particular diabetes mellitus [DM], dyslipidaemia, and hyperhomocysteinaemia are all associated with OS. As such, it is becoming increasingly apparent that novel antioxidant therapies, including the gene transfer of antioxidant enzymes, are potentially valuable in the treatment of CVD. In this review, the aetiology of OS and CVD is discussed with particular emphasis on NO. The interactions of risk factors and how this pathophysiology relates to the design of effective novel strategies to treat CVD is also considered. Particular emphasis is also placed on OS and cardiovascular surgery.
Export Options
About this article
Cite this article as:
Jeremy Y. Jamie, Shukla Nilima, Muzaffar Saima, Handley Alexandra and Angelini D. Gianni, Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery, Current Vascular Pharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570161043385691
DOI https://dx.doi.org/10.2174/1570161043385691 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE2 and Diabetic Complications
Current Pharmaceutical Design Modulation of Inflammation as a Way of Delaying Alzheimer's Disease Progression: The Diet's Role
Current Alzheimer Research Magnetic Resonance Spectroscopy Biomarkers in Term Perinatal Asphyxial Encephalopathy: From Neuropathological Correlates to Future Clinical Applications
Current Pediatric Reviews Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Involvement of Dendritic Cells in Allograft Rejection New implications of Dendritic Cell-Endothelial Cell Interactions
Mini-Reviews in Medicinal Chemistry Novel Therapeutics in Glaucoma Management
Current Neuropharmacology Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Subject Index to Volume 1
Vascular Disease Prevention (Discontinued) Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmaceutical Polymeric Nanoparticles Prepared by the Double Emulsion- Solvent Evaporation Technique
Recent Patents on Drug Delivery & Formulation Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Subject Index Volume 6
Mini-Reviews in Medicinal Chemistry Topical Antimicrobials for Burn Wound Infections
Recent Patents on Anti-Infective Drug Discovery NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Concise Review of the Rationale for Pulmonary Embolism Treatment and Endovascular Device Therapies
Current Cardiology Reviews Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Current Pharmaceutical Design